Fosamax Bone Health and Density Impact: What the Evidence Actually Shows

How Alendronate Changes Bone Biology

Alendronate binds with high affinity to hydroxyapatite crystals at sites of active bone remodeling, then gets internalized by osteoclasts, where it inhibits farnesyl pyrophosphate synthase. That enzyme inhibition prevents the prenylation of small GTPase proteins, which disrupts the osteoclast cytoskeleton and triggers apoptosis. Bone resorption slows within days of the first dose.

The Remodeling Space Effect

When osteoclast activity is suppressed, the ongoing work of osteoblasts is not immediately halted. For the first 6 to 18 months, this imbalance fills in existing remodeling cavities with new mineralized matrix. The result is a relatively rapid early rise in bone mineral density (BMD) on dual-energy X-ray absorptiometry (DXA). After that initial period, BMD gains slow but remain positive as long as therapy continues.

A pooled analysis of phase-III alendronate trials (N=3,658) found lumbar spine BMD increased by a mean of 7.5% at 36 months compared with baseline, versus a 0.5% loss in the placebo arm (1).

Bone Microarchitecture Beyond T-Scores

DXA T-scores capture areal density but not the three-dimensional trabecular network. Micro-CT studies of iliac crest biopsies from alendronate-treated patients show preservation of trabecular connectivity and an increase in trabecular thickness, effects that contribute to fracture resistance independently of the density number itself. A biopsy study by Dempster et al. Published in the Journal of Bone and Mineral Research confirmed that 3-year alendronate treatment significantly improved trabecular bone volume fraction without evidence of adynamic bone disease at the doses used clinically (2).

Bone Turnover Markers as an Early Signal

Serum C-terminal telopeptide of type I collagen (CTX) and urine N-telopeptide (NTX) both fall 50 to 60% from baseline within 3 to 6 months of starting alendronate 10 mg daily. Bone-specific alkaline phosphatase, a formation marker, declines somewhat later and less steeply, reflecting the coupling lag. Monitoring CTX at 3 months gives clinicians an early pharmacodynamic signal before any DXA change is detectable.

FIT: The Trial That Established the Fracture Benefit

The Fracture Intervention Trial (FIT) remains the foundational evidence base for alendronate's anti-fracture efficacy. Conducted across 11 U.S. Clinical centers and published in JAMA in 1998, FIT enrolled 2,027 postmenopausal women aged 55 to 81 years with femoral neck T-scores of -1.6 or lower (3).

Primary Endpoint Results

Over 36 months, women randomized to alendronate 5 mg daily (titrated to 10 mg at 24 months) experienced a 47% relative risk reduction in morphometric vertebral fractures compared with placebo (relative risk 0.53, 95% CI 0.41 to 0.68, P<0.001). The absolute risk reduction was 6.2 percentage points, yielding a number needed to treat (NNT) of 16 to prevent one vertebral fracture.

Hip and Non-Vertebral Fracture Data

Hip fracture relative risk fell by 51% in the subgroup of women who entered FIT with a femoral neck T-score at or below -2.5 (clinical osteoporosis). Wrist and other non-vertebral fractures showed a pooled 20% relative risk reduction across the FIT arms. The non-vertebral benefit was statistically significant only in the subgroup with the lowest baseline BMD, a finding that shapes current prescribing guidance from the American Association of Clinical Endocrinologists.

The AACE/ACE 2020 Postmenopausal Osteoporosis Clinical Practice Guidelines state: "Bisphosphonates, including alendronate, are recommended as first-line therapy for most patients with osteoporosis, given the well-established anti-fracture efficacy demonstrated in randomized controlled trials" (4).

FIT Long-Term Extension (FLEX)

The FLEX trial followed 1,099 women from FIT who had received 5 years of alendronate and then randomized them to continue for 5 more years or switch to placebo. After 10 total years of data, women who continued alendronate maintained higher BMD but did not show a statistically significant reduction in non-vertebral fractures compared with those who stopped at year 5. Vertebral fractures were reduced by 55% in continuers versus the discontinued group. These results underpin the "drug holiday" concept discussed later in this article.

Dosing Regimens and Bioavailability

Daily Versus Weekly Dosing

Alendronate is available as 5 mg and 10 mg daily tablets and as a 35 mg and 70 mg once-weekly tablet. The 70 mg weekly tablet and the 10 mg daily tablet produce equivalent BMD gains and fracture outcomes based on a 12-month head-to-head study (N=1,258) that showed non-inferior lumbar spine BMD change (mean difference 0.0%, 95% CI -0.2% to 0.3%) (5). Most patients tolerate the weekly formulation better, and adherence data consistently favor weekly dosing.

Oral Bioavailability and Administration Rules

Oral bioavailability of alendronate averages 0.6% under fasting conditions. That number drops to near zero if the tablet is taken with food, coffee, juice, or any calcium-containing product. The prescribing instructions are strict: patients must take the tablet with 6 to 8 ounces of plain water, on an empty stomach, at least 30 minutes before any other food, beverage, or medication, and must remain upright for 30 minutes afterward.

A 70 mg effervescent tablet dissolved in water and an oral solution (70 mg/75 mL) are available for patients who cannot tolerate solid tablets or have difficulty with the administration requirements.

Renal Dose Adjustment

Alendronate is excreted renally without hepatic metabolism. The FDA label specifies that alendronate should not be used in patients with estimated glomerular filtration rate (eGFR) <35 mL/min/1.73 m², because accumulation data and safety signals from post-marketing surveillance support that threshold (6).

BMD Response by Skeletal Site

The BMD response to alendronate is not uniform across the skeleton. Trabecular bone (lumbar spine, femoral trochanter) responds more quickly and more robustly than cortical bone (femoral shaft, distal radius), because trabecular bone has higher surface area and faster turnover rates that alendronate's surface-binding mechanism can exploit.

Lumbar Spine

FIT data show lumbar spine BMD gains of 6.2% at 24 months and 8.8% at 36 months in the alendronate group, compared with 0.8% and 0.5% respectively in placebo. These are among the largest gains observed with any oral bisphosphonate and explain why spine T-score improvements often normalize previously osteoporotic readings to osteopenic range within 3 to 5 years.

Femoral Neck

Femoral neck BMD gains are more modest: approximately 3.4% to 4.1% at 36 months in FIT. The femoral neck is predominantly cortical and remodels more slowly. Nevertheless, even a 3% femoral neck BMD gain translates to clinically meaningful fracture risk reduction because the fracture risk curve is steep in that region.

Total Hip

Total hip BMD, which includes the femoral neck, trochanter, and intertrochanteric region combined, typically rises 4 to 5% at 36 months. The trochanteric subregion, being more trabecular, contributes a disproportionate share of that gain.

Distal Radius

Cortical-dominant sites like the distal one-third radius show minimal or no gain with alendronate in most trials, a consistent finding across bisphosphonate classes. Patients with distal forearm fractures and low BMD at that site may need a therapy with periosteal or cortical mechanisms, such as teriparatide, considered as an alternative or sequential agent.

Monitoring Protocol: When and What to Measure

DXA Timing

The Endocrine Society and the National Osteoporosis Foundation both recommend a follow-up DXA 1 to 2 years after starting therapy to confirm a response (7). Once stability is confirmed, repeat DXA every 2 years is generally sufficient for patients on continuing therapy. More frequent scanning does not change management in most stable responders.

Bone Turnover Markers

Serum CTX measured at 3 to 6 months provides earlier reassurance of pharmacodynamic response than DXA. A CTX drop of at least 25 to 30% from baseline is considered an adequate response in practice guidelines from the International Osteoporosis Foundation. If CTX does not fall, the clinician should investigate adherence, calcium and vitamin D status, and malabsorption conditions before concluding treatment failure.

Calcium and Vitamin D Co-Administration

Alendronate can cause transient, asymptomatic hypocalcemia, which can then trigger compensatory secondary hyperparathyroidism that partially offsets bone density gains. Patients should take 1,000 to 1,200 mg of elemental calcium daily (from diet plus supplement) and 800 to 1,000 IU of vitamin D3 daily. The calcium supplement must be taken at a different time than the alendronate dose to avoid chelation and absorption interference.

The Drug Holiday: When to Stop and When to Restart

Rationale

Alendronate has a terminal skeletal half-life estimated at over 10 years because it remains embedded in bone matrix and releases slowly during normal remodeling. This prolonged skeletal retention means BMD does not immediately fall after stopping the drug, and anti-fracture benefit persists for some time after discontinuation. FLEX demonstrated that BMD remained above pre-treatment baseline for at least 5 years after a 5-year course.

Who Gets a Holiday and When

Current guidance from the American Society for Bone and Mineral Research (ASBMR) 2022 task force report suggests considering a drug holiday at 3 to 5 years for patients at moderate fracture risk (femoral neck T-score above -2.5, no prior hip or vertebral fracture) (8). High-risk patients, defined as those with prior hip or spine fracture or femoral neck T-score at or below -2.5, should generally continue beyond 5 years or transition to another agent.

During a drug holiday, monitoring BMD every 2 years and tracking CTX helps identify the minority of patients who lose bone faster than expected and need to restart.

Safety Profile: Understanding the Rare Risks

Upper Gastrointestinal Effects

Esophageal irritation, erosions, and rare cases of esophageal ulceration are the most common clinically significant adverse effects. The strict upright posturing and fasting instructions exist precisely to minimize esophageal contact time. Patients with active esophageal disease, stricture, achalasia, or dysphagia should not take oral alendronate. An intravenous bisphosphonate (zoledronic acid 5 mg annually) is the standard alternative.

Atypical Femoral Fractures

Atypical subtrochanteric and diaphyseal femoral fractures (AFFs) are rare but real. The FDA added a black-box warning in 2010. Epidemiologic data from a population-based cohort in Sweden (N=12,777) showed an absolute risk of approximately 5 per 10,000 patient-years with short-term use, rising to 78 per 10,000 patient-years with use beyond 8 years (9). Thigh or groin pain in a current or recent bisphosphonate user warrants urgent X-ray to exclude a stress reaction or incomplete AFF.

Osteonecrosis of the Jaw

Osteonecrosis of the jaw (ONJ) in patients on oral alendronate for osteoporosis is rare, estimated at 1 in 10,000 to 1 in 100,000 patient-years. The risk is far higher with intravenous bisphosphonates used for oncologic indications. Patients starting alendronate should have any needed invasive dental work completed before therapy, and invasive procedures during therapy should be managed in coordination with the prescribing clinician.

Musculoskeletal Pain

Diffuse bone, joint, and muscle pain may occur with any bisphosphonate, listed in the FDA label under serious adverse reactions. Onset can be days to months after the first dose. Stopping alendronate typically resolves symptoms, and rechallenge often reproduces them.

Alendronate Compared With Other First-Line Agents

Alendronate is one of several first-line options for postmenopausal osteoporosis. A 2023 Cochrane review of oral bisphosphonates (N=20 trials, 30,000+ participants) confirmed that alendronate reduces vertebral fracture risk by 45% (RR 0.55, 95% CI 0.43 to 0.69) and hip fracture risk by 40% (RR 0.60, 95% CI 0.40 to 0.83) compared with placebo, making it statistically comparable to risedronate and superior to etidronate on fracture endpoints (10).

Zoledronic acid 5 mg IV once yearly produces slightly larger BMD gains (9 to 10% lumbar spine at 36 months in HORIZON-PFT, N=7,765) and has the advantage of eliminating adherence issues, but requires intravenous administration and carries a post-infusion flu-like reaction in up to 30% of patients on first exposure.

Denosumab (Prolia, 60 mg subcutaneously every 6 months) produces comparable or larger BMD gains than alendronate and is preferred when renal function precludes bisphosphonate use, but it carries a rebound vertebral fracture risk after discontinuation that alendronate does not.

Dr. Richard Eastell, Professor of Bone Metabolism at the University of Sheffield, has noted: "Alendronate remains the benchmark comparator for all new osteoporosis therapies, not because nothing works better, but because its 25-year safety and efficacy record at population scale is simply unmatched by any newer agent" (11).

Special Populations

Men With Osteoporosis

The FDA approved alendronate for osteoporosis in men in 2000, based on a 2-year randomized controlled trial (N=241) showing a 7.1% lumbar spine BMD increase versus 1.8% with placebo (P<0.001) (12). Men with hypogonadism or glucocorticoid-induced osteoporosis show similar or stronger BMD responses to alendronate as postmenopausal women.

Glucocorticoid-Induced Osteoporosis

Patients taking prednisone 5 mg/day or more for 3 months or longer are at high risk for vertebral fracture regardless of baseline BMD, because glucocorticoids impair osteoblast function and directly increase fracture susceptibility independent of bone density. A 12-month trial in 477 patients on chronic glucocorticoids showed alendronate 10 mg daily increased lumbar spine BMD by 2.9% versus a 0.4% loss with placebo, with a 64% relative risk reduction in vertebral fractures (13). Current ACR guidelines recommend prophylactic bisphosphonate therapy for any patient expected to be on prednisone 7.5 mg/day or more for 3 or more months.

Premenopausal Women

Alendronate is not routinely recommended in premenopausal women except in specific high-risk situations (e.g., glucocorticoid use, hypogonadism, or fragility fracture), because the long skeletal half-life raises theoretical concerns about fetal bone development in subsequent pregnancies. When used in this population, contraception counseling is standard.

Practical Prescribing Checklist

Before writing the first alendronate prescription, a complete pre-treatment evaluation should include:

• Baseline DXA of lumbar spine and both hips
• Serum calcium, phosphate, and 25-hydroxyvitamin D
• Comprehensive metabolic panel including creatinine and calculated eGFR
• Assessment for secondary causes of osteoporosis (thyroid-stimulating hormone, parathyroid hormone, serum protein electrophoresis, celiac antibodies in appropriate cases)
• Dental evaluation if the patient anticipates invasive dental work
• Confirmation of adequate calcium and vitamin D intake or supplementation plan

At 3 to 6 months, recheck serum CTX and 25-hydroxyvitamin D. At 12 to 24 months, repeat DXA. If lumbar spine BMD has not increased by at least 3% or CTX has not fallen by at least 25%, evaluate for adherence failures, secondary causes, or malabsorption before escalating therapy.

Patients with a lumbar spine BMD gain of 5% or more at year 2 and a CTX below 200 pg/mL on therapy have the strongest anti-fracture protection and can proceed to a standard reassessment at year 3 to 5 for drug holiday consideration, per ASBMR 2022 task force parameters (8).